OBJECTIVES: Evidence suggests that doxycycline might have disease-modifying properties in osteoarthritis. However, the clinically relevant question as to whether doxycycline also modifies symptoms in knee osteoarthritis is unanswered. The objective of this study was to investigate the effectiveness of doxycycline on pain and daily functioning in symptomatic knee osteoarthritis. METHODS: A 24-week, randomised, triple-blind, placebo controlled trial on the symptomatic effectiveness of doxycycline twice a day 100 mg in knee osteoarthritis patients according to the clinical and radiological American College of Rheumatology classification criteria. The primary endpoint was the difference in the proportion of participants in both study groups achieving a clinical response defined by the OMERACT-OARSI set of responder criteria. Secondary endpoints included pain, stiffness, daily functioning, patient global assessment, quality of life, osteoarthritis-related medication and side effects. RESULTS:232 patients were randomly assigned. At study end, 31% of participants met the primary endpoint in both groups. Except for more adverse events in the doxycycline group, no differences were also found on the secondary endpoints. CONCLUSIONS:Doxycycline is not effective in reducing symptoms in knee osteoarthritis patients over a 24-week study period, but is associated with an increased risk of adverse events. Although a possible structure-modifying effect of doxycycline was previously suggested, this is not accompanied by symptom relief in the short and medium term. Dutch Trial Register no NTR1111.
RCT Entities:
OBJECTIVES: Evidence suggests that doxycycline might have disease-modifying properties in osteoarthritis. However, the clinically relevant question as to whether doxycycline also modifies symptoms in knee osteoarthritis is unanswered. The objective of this study was to investigate the effectiveness of doxycycline on pain and daily functioning in symptomatic knee osteoarthritis. METHODS: A 24-week, randomised, triple-blind, placebo controlled trial on the symptomatic effectiveness of doxycycline twice a day 100 mg in knee osteoarthritispatients according to the clinical and radiological American College of Rheumatology classification criteria. The primary endpoint was the difference in the proportion of participants in both study groups achieving a clinical response defined by the OMERACT-OARSI set of responder criteria. Secondary endpoints included pain, stiffness, daily functioning, patient global assessment, quality of life, osteoarthritis-related medication and side effects. RESULTS: 232 patients were randomly assigned. At study end, 31% of participants met the primary endpoint in both groups. Except for more adverse events in the doxycycline group, no differences were also found on the secondary endpoints. CONCLUSIONS:Doxycycline is not effective in reducing symptoms in knee osteoarthritispatients over a 24-week study period, but is associated with an increased risk of adverse events. Although a possible structure-modifying effect of doxycycline was previously suggested, this is not accompanied by symptom relief in the short and medium term. Dutch Trial Register no NTR1111.
Authors: Grace H Lo; Timothy E McAlindon; Gillian A Hawker; Jeffrey B Driban; Lori Lyn Price; Jing Song; Charles B Eaton; Marc C Hochberg; Rebecca D Jackson; C Kent Kwoh; Michael C Nevitt; Dorothy D Dunlop Journal: Arthritis Rheumatol Date: 2015-11 Impact factor: 10.995
Authors: Kevin J Anstrom; Imre Noth; Kevin R Flaherty; Rex H Edwards; Joan Albright; Amanda Baucom; Maria Brooks; Allan B Clark; Emily S Clausen; Michael T Durheim; Dong-Yun Kim; Jerry Kirchner; Justin M Oldham; Laurie D Snyder; Andrew M Wilson; Stephen R Wisniewski; Eric Yow; Fernando J Martinez Journal: Respir Res Date: 2020-03-12
Authors: Carolien H Teirlinck; Arianne P Verhagen; Elja A E Reijneveld; Jos Runhaar; Marienke van Middelkoop; Leontien M van Ravesteyn; Lotte Hermsen; Ingrid B de Groot; Sita M A Bierma-Zeinstra Journal: Int J Environ Res Public Health Date: 2020-10-10 Impact factor: 3.390
Authors: Cale A Jacobs; Caitlin E W Conley; Virginia Byers Kraus; Drew A Lansdown; Brian C Lau; Xiaojuan Li; Sharmila Majumdar; Kurt P Spindler; Nicole G Lemaster; Austin V Stone Journal: Trials Date: 2022-01-31 Impact factor: 2.279